Treating Stimulant Addiction With Repetitive Transcranial Magnetic Stimulation

VA Office of Research and Development1 site in 1 country30 target enrollmentFebruary 5, 2021

ConditionsStimulant Use Disorder Substance-related Disorders

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Stimulant Use Disorder
Sponsor: VA Office of Research and Development
Enrollment: 30
Locations: 1
Primary Endpoint: Number of Participants Relapsed
Status: Terminated
Last Updated: 8 months ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to establish a new treatment (repetitive transcranial stimulation (rTMS)) for Veterans with stimulant use disorder (SUD). Despite the large public health burden imposed by SUD, there is currently no FDA-approved or widely recognized effective somatic treatment. rTMS may be a promising treatment option for SUD. In this study, we will demonstrate the feasibility of applying rTMS to Veterans with SUD, examine the efficacy of rTMS in the treatment of SUD, and explore biomarkers that may guide patient selection for rTMS treatment and predict treatment response.

Registry

clinicaltrials.gov

Start Date

February 5, 2021

End Date

June 1, 2024

Last Updated

8 months ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

VA Office of Research and Development

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Structured Clinical Interview for DSM Disorders (SCID) confirmed diagnosis of SUD, severe
•Last use of stimulants \>1 and \<6 weeks
•Stable medication regimen (no change in dose or agents between 2 weeks prior to the start of and throughout the treatment phase of the study)
•Stable social environment and housing to enable regular attendance at clinic visits.
•Ability to undergo cognitive testing, functional magnetic resonance imaging (fMRI) scans, and rTMS (no contraindications)
•Intelligence Quotient (IQ) \> 80
•Stable medical health
•Veteran at Palo Alto VA's Addiction Treatment Services

Exclusion Criteria

•Pregnant or lactating female
•History of prior adverse reaction to TMS
•On medications thought to significantly lower seizure threshold, e.g.:
•clozapine
•chlorpromazine
•clomipramine
•bupropion \> 400 mg/day
•Use of direct dopaminergic antagonists or agonists
•History of seizures or conditions known to substantially increase risk for seizures
•Implants or medical devices incompatible with TMS